HC Wainwright Boosts Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of Gossamer Bio in a research note issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.07) per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.20) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at ($0.07) EPS.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. The firm had revenue of $13.80 million during the quarter, compared to analyst estimates of $7.53 million.

GOSS has been the topic of a number of other reports. The Goldman Sachs Group cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wedbush reaffirmed a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th. Finally, Barclays downgraded Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.43.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $0.34 on Monday. Gossamer Bio has a 52 week low of $0.32 and a 52 week high of $3.87. The company has a market capitalization of $80.95 million, a PE ratio of -0.46 and a beta of 2.08. The company has a 50 day moving average price of $1.56 and a two-hundred day moving average price of $2.41.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after buying an additional 5,427,302 shares in the last quarter. Corient Private Wealth LLC grew its holdings in shares of Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after acquiring an additional 3,825,879 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Gossamer Bio by 629.3% in the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after acquiring an additional 3,123,081 shares in the last quarter. Bank of America Corp DE increased its position in shares of Gossamer Bio by 4,196.2% in the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock valued at $7,579,000 after acquiring an additional 2,814,824 shares during the last quarter. Finally, UBS Group AG raised its holdings in Gossamer Bio by 785.7% during the third quarter. UBS Group AG now owns 2,770,046 shares of the company’s stock worth $7,285,000 after acquiring an additional 2,457,304 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Neutral Sentiment: Market data shows multiple reports of a large “increase” in short interest for March, but the published figures are inconsistent or zero (short interest = 0 shares; days‑to‑cover = 0.0), suggesting a data anomaly rather than clear new shorting pressure. (May indicate noise rather than a firm fundamental change.)
• Neutral Sentiment: Cantor Fitzgerald’s coverage actions are mixed in feeds: one item notes a downgrade action while another notes a reaffirmed “neutral” rating — the net effect is limited additional negative guidance but confirms tepid analyst sentiment. Cantor Fitzgerald downgrades Gossamer Bio (GOSS)
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Gossamer, signaling potential shareholder litigation tied to recent developments and increasing legal overhang. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
• Negative Sentiment: Levi & Korsinsky announced a shareholders’ alert and investigation into Gossamer, reinforcing regulatory/litigation concerns and adding to investor uncertainty around the company’s pivotal seralutinib program and the PROSERA Phase 3 outcome. Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS)
• Negative Sentiment: Press coverage highlights a clinical setback and declining investor confidence around Gossamer’s lead program (seralutinib/PROSERA), which directly pressures valuation for a clinical‑stage biotech reliant on a single pivotal asset. Investor Confidence Wanes Following Gossamer Bio’s Clinical Setback

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.